DXCM -- Q1 2026 Earnings Preview
Dexcom enters Q1 with a cleaner setup than it had a year ago, but the bar is no longer just stabilization. Q4 revenue was $1.26B, up 13% YoY, with U.S. revenue of $891.5M and international revenue of $368.1M. Non-GAAP operating income reached $331.5M, while diluted EPS was $0.68.
The Q1 debate is whether G7, Stelo, pharmacy-channel execution, and international adoption can sustain low-teens growth while margins hold. The FY2026 guide calls for revenue of $5.16B to $5.25B, reported revenue growth of 11% to 13%, non-GAAP gross margin of 63% to 64%, and adjusted EBITDA margin of 30% to 31%.
| Metric | FY2026 Guide | Preview Read | |---|---:|---| | Revenue | $5.16B to $5.25B | Requires Q1 growth to stay solidly double digit | | Reported revenue growth | 11% to 13% | The key post-2024 recovery benchmark | | Non-GAAP gross margin | 63% to 64% | Watch manufacturing yield, rebate/channel mix, and launch costs | | Non-GAAP operating margin | 22% to 23% | Must show leverage after Q4 strength | | Adjusted EBITDA margin | 30% to 31% | Quality test for growth reinvestment |
Revenue growth reaccelerated through 2025, but Q4's 13% reported growth is close to the FY2026 guide range. Q1 needs to show that the recovery is durable rather than a temporary rebound from easier 2024 comparisons.
Non-GAAP operating income rose sharply in H2 2025. The question is whether Q1 can preserve operating leverage while the company funds Stelo, G7 adoption, and commercial execution.
The U.S. remains the main swing factor. U.S. revenue recovered to $891.5M in Q4 and U.S. organic growth was 11%, down from 21% in Q3. International revenue was $368.1M, with organic growth of 15%. A high-quality Q1 would show continued international strength plus no new U.S. access/channel issue.
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |---|---:|---:|---:|---:| | Revenue | $1.04B | $1.16B | $1.21B | $1.26B | | U.S. revenue | $750.5M | $841.0M | $851.9M | $891.5M | | International revenue | $285.5M | $316.1M | $357.4M | $368.1M | | Organic revenue growth | +14% | +15% | +20% | +12% | | Non-GAAP operating income | $143.1M | $221.8M | $272.9M | $331.5M | | Diluted EPS | $0.27 | $0.45 | $0.70 | $0.68 |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Read | |---|---:|---:|---:|---| | Sensor revenue | $997.2M | $1.12B | $1.18B | Core recurring-like driver | | Sensor revenue growth | 17% | 18% | 23% | Reaccelerated before Q4 component detail became unavailable in Daloopa | | Hardware revenue | $38.8M | $39.3M | $34.2M | Smaller and declining mix | | Hardware revenue growth | -42% | -31% | -19% | Mix shift toward sensors is positive for recurring revenue quality | | Sensor revenue % of total | 96% | 97% | 97% | Supports higher-quality growth |
This is a growth-quality print. Dexcom has already shown that revenue can recover from the 2024 disruption; the next test is whether the company can grow inside the 11%-13% FY2026 guide without sacrificing margin. Q4 operating income of $323.0M and non-GAAP operating income of $331.5M make margin sustainability a central call topic.
The highest-signal commentary will be U.S. new-patient starts, pharmacy channel progress, payer access, G7 conversion, Stelo adoption, international CGM penetration, and Libre competition. A clean print should pair U.S. growth stability with ongoing international momentum and reaffirm the 30%-31% adjusted EBITDA margin guide.
| Catalyst | Timing | What Matters | |---|---|---| | Q1 U.S. growth | Apr 30 | Stability after Q4 U.S. organic growth of 11% | | International adoption | Apr 30 | Sustain Q4 international organic growth of 15% | | Stelo and G7 commentary | Apr 30 call | Evidence of category expansion without margin dilution | | FY2026 guide | Apr 30 | Reaffirm $5.16-$5.25B / high revenue guide | | Margin guide | Apr 30 | Confidence in 63%-64% / high non-GAAP gross margin and 30%-31% / high adjusted EBITDA margin |
| Quarter | Revenue | Diluted EPS | Quality Signal | |---|---:|---:|---| | Q4 2025 | $1.26B | $0.68 | Strong margin and low-teens growth | | Q3 2025 | $1.21B | $0.70 | Best recent organic-growth quarter | | Q2 2025 | $1.16B | $0.45 | Growth and operating leverage improved | | Q1 2025 | $1.04B | $0.27 | Baseline for the Q1 2026 comparison |